Patents by Inventor Andrew Ayscough

Andrew Ayscough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100063065
    Abstract: The invention discloses compounds of formula (I); wherein: R is a carboxylic acid or a derivative thereof; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, halo or trihalomethyl; R2 is aryl, heteroaryl, arylalkyl or heteroarylalkyl; R3 is H or F; and L is a linking group comprising a chain of from 2 to 8 atoms linking R and the carbonyl group (A); and pharmaceutically acceptable derivatives thereof, useful for treating disorders mediated by peroxisome-proliferator-activated receptor (PPAR) subtype ? (PPAR?). The compounds of the invention are therefore useful in the treatment of metabolic syndrome, obesity, type-II diabetes, dyslipidemia, wound healing, inflammation, neurodegenerative disorders and multiple sclerosis.
    Type: Application
    Filed: September 28, 2006
    Publication date: March 11, 2010
    Applicant: Inpharmatica Limited
    Inventors: Andrew Ayscough, David Rodyney Owen, Paul Meo, David James Pearson, Yvonne Walker, Richard Justin Boyce, Fabio Zuccotto
  • Publication number: 20060089363
    Abstract: Compounds of formula (II) have antibacterial activity: wherein Q represents a radical of formula —N(OH)CH(?0) or formula —C(?O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of formula —N(OH)CH(?0), a hydroxy, halo or amino group; R2 represents a group R10-(V)n-(ALK)m- wherein R10 represents hydrogen, or an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, V represents —NH—, —O— or —S—, m and n are independently 0 or 1; R3 represents the side chain of a natural or non-natural alpha amino acid; R4 represents hydrogen or C1-C3 alkyl; Y represents N or CH; ring A is optionally substituted on one or more ring carbon atoms by C1-C3 alkyl, C1-C3 alkoxy, or halo; and R5 represents a group (IIA): wherein m is 0 or 1; Alk1 represents a
    Type: Application
    Filed: April 9, 2003
    Publication date: April 27, 2006
    Applicant: VERNALIS (OXFORD) LIMITED
    Inventors: Andrew Ayscough, Kenneth Keavey
  • Publication number: 20050222189
    Abstract: Compounds formula (IA) or (IB), wherein W represents HO(C?O)—, HONH(C?O)— or H(C?O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.
    Type: Application
    Filed: February 20, 2003
    Publication date: October 6, 2005
    Applicants: VERNALIS (OXFORD) LTD, LABORATORIES SERONO S.A.
    Inventors: Andrew Ayscough, Stephen Davies, Gilles Pain, Jean-Yves Gillon